Gynecologic oncology reports
Audio Summaries

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience

Sep 23, 2026

The authors aimed to evaluate the efficacy and safety of trabectedin combined with pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer who progressed after prior treatment with PARP inhibitors. In a retrospective study of 25 patients, they found a 24% objective response rate and a median progression-free survival of 7.9 months, suggesting that this combination therapy may be a viable treatment option for this specific patient population. The study highlights the need for further prospective research to optimize treatment sequencing following PARP inhibitor exposure.

Fertility-sparing surgery for a patient with a pre-operative suspected diagnosis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A case report

Sep 23, 2026

The authors explore the feasibility of fertility-sparing surgery for a patient with a suspected Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP), highlighting the case of a 34-year-old woman who underwent a myomectomy instead of a total hysterectomy due to her desire for future fertility. Despite initial concerns regarding the tumor's malignancy, follow-up imaging revealed no abnormalities, and final pathology confirmed a benign diagnosis. This case suggests that myomectomy without morcellation may be a viable treatment option for patients with STUMP who wish to preserve their fertility.

Abscopal effect following palliative radiotherapy after cemiplimab in recurrent cervical cancer: a case report

Sep 23, 2026

This case report investigates the occurrence of the abscopal effect in a patient with recurrent cervical cancer who received palliative radiotherapy following cemiplimab treatment. The authors aim to demonstrate how localized radiotherapy can induce regression of distant metastatic lesions, potentially enhancing systemic antitumor immunity in conjunction with immune checkpoint inhibitors. The findings suggest a promising synergy between radiotherapy and PD-1 blockade, warranting further research into mechanisms and treatment strategies to optimize this effect in advanced gynecologic cancers.

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report

Sep 20, 2026

The authors investigate the efficacy of combining temozolomide and olaparib in treating a patient with ARID1A-mutated uterine carcinosarcoma, a scenario that has not been previously reported in clinical practice. The case study demonstrates a complete radiographic response after four cycles of this regimen, suggesting potential benefits for biomarker-selected patients with this cancer type. The findings support further prospective studies to evaluate this treatment combination in genomically characterized gynecologic cancers.

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting

Sep 14, 2026

The authors aimed to evaluate the real-world effectiveness and toxicity of Mirvetuximab Soravtansine (MIRV) in patients with recurrent ovarian cancer, as previous trials had stringent eligibility criteria. In a retrospective analysis of 66 patients, they found a median overall survival of 16.4 months and a progression-free survival of 5.3 months, with performance status significantly impacting survival outcomes. The study highlights the common occurrence of toxicity and the need for careful management, particularly in patients with poorer performance status.

Markedly elevated alpha-fetoprotein leading to the diagnosis of high-grade endometrial carcinoma during hepatocellular carcinoma surveillance

Sep 12, 2026

The authors investigate the potential of alpha-fetoprotein (AFP) as a marker for aggressive histologic variants of endometrial carcinoma, particularly in patients undergoing surveillance for hepatocellular carcinoma (HCC). They present a case of a 70-year-old woman whose significantly elevated AFP levels led to the diagnosis of high-grade endometrial carcinoma, despite no evidence of HCC, underscoring the need to consider non-hepatic causes of AFP elevation in clinical practice.

Intraperitoneal OK-432 infusion for postoperative lymphatic leakage in gynecologic tumors

Sep 5, 2026

This study investigates the efficacy and safety of intraperitoneal OK-432 infusion as a treatment for postoperative lymphatic leakage in patients who have undergone radical surgery for gynecologic tumors. The results indicate that this treatment significantly reduces drainage volume and time to drainage tube removal, with no observed complications or tumor recurrences, suggesting it may be a viable alternative to existing management strategies for this complication.

Molecular subtypes of stage III vulvar squamous cell carcinoma predict recurrence and survival outcomes

Sep 5, 2026

The authors aimed to investigate the association between molecular subtypes of stage III vulvar squamous cell carcinoma (vSCC) and oncologic outcomes, specifically recurrence and disease-specific mortality. Their findings indicate that while HPV-independent tumors, particularly those with TP53 mutations, are linked to worse survival outcomes, the molecular classification did not significantly predict recurrence rates within five years. This study highlights the potential for molecularly informed risk stratification and treatment strategies in managing stage III vSCC.

The use of ex-vivo in-vitro maturation of ovarian tissues oocytes (OTO-IVM) for fertility preservation in gynaecologic cancers

Sep 5, 2026

The authors investigate the potential of ex-vivo in-vitro maturation of ovarian tissue oocytes (OTO-IVM) as a fertility preservation method for women with gynaecologic cancers, particularly when traditional techniques are unsuitable. They present a case series of four women who underwent this procedure during oncologic surgeries, highlighting the experimental nature of OTO-IVM and its potential as a viable option for fertility preservation in challenging cases. The study underscores the need for further evidence to support the effectiveness of OTO-IVM in achieving live births.

Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship

Sep 5, 2026

The authors investigate the prolonged latency period between the diagnosis of a serous borderline ovarian tumor (SBOT) and its progression to low-grade serous ovarian carcinoma (LGSOC), presenting a case where this transition occurred after 35 years. They provide molecular evidence of a clonal relationship between the two tumors through the identification of a BRAF V600E mutation, which also guided targeted therapy for the patient. This case underscores the importance of molecular testing in understanding tumor progression and informing treatment strategies.